These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 7805177

  • 1. In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice.
    Heike Y, Takahashi M, Ohira T, Arioka H, Funayama Y, Nishio K, Ogasawara H, Saijo N.
    Cancer Chemother Pharmacol; 1995; 35(3):200-4. PubMed ID: 7805177
    [Abstract] [Full Text] [Related]

  • 2. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
    Ohmori T, Morikage T, Sugimoto Y, Fujiwara Y, Kasahara K, Nishio K, Ohta S, Sasaki Y, Takahashi T, Saijo N.
    Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
    Lee YS, Nishio K, Ogasawara H, Funayama Y, Ohira T, Saijo N.
    Cancer Res; 1995 Mar 01; 55(5):1075-9. PubMed ID: 7866991
    [Abstract] [Full Text] [Related]

  • 6. Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines.
    Kawamura-Akiyama Y, Kusaba H, Kanzawa F, Tamura T, Saijo N, Nishio K.
    Lung Cancer; 2002 Oct 01; 38(1):43-50. PubMed ID: 12367792
    [Abstract] [Full Text] [Related]

  • 7. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F, Livartowski A, De Cremoux P, Bourgeois Y, Arvelo F, Pouillart P, Poupon MF.
    Clin Cancer Res; 2000 May 01; 6(5):2075-86. PubMed ID: 10815935
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin-resistant cell line.
    Oshita F, Fujiwara Y, Saijo N.
    J Cancer Res Clin Oncol; 1992 May 01; 119(1):28-34. PubMed ID: 1400562
    [Abstract] [Full Text] [Related]

  • 10. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N.
    Cancer Res; 1989 Aug 01; 49(15):4098-102. PubMed ID: 2472873
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The subunits of glutamate cysteine ligase enhance cisplatin resistance in human non-small cell lung cancer xenografts in vivo.
    Fujimori S, Abe Y, Nishi M, Hamamoto A, Inoue Y, Ohnishi Y, Nishime C, Matsumoto H, Yamazaki H, Kijima H, Ueyama Y, Inoue H, Nakamura M.
    Int J Oncol; 2004 Aug 01; 25(2):413-8. PubMed ID: 15254739
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic correlation between experimental and clinical effects on human non-small cell lung cancers of cis-diammineglycolatoplatinum (254-S) and cis-diamminedichloroplatinum.
    Koenuma M, Kasai H, Uchida N, Wada T, Hattori M, Oguma T, Totani T, Inaba M.
    Anticancer Res; 1995 Aug 01; 15(2):417-21. PubMed ID: 7763015
    [Abstract] [Full Text] [Related]

  • 14. Alteration of type II regulatory subunit of cAMP-dependent protein kinase in human cisplatin-resistant cells as a basis of collateral sensitivity to 8-chloro-cAMP.
    Nishio K, Morikage T, Kubota N, Ohmori T, Takeda Y, Fujiwara Y, Miki K, Abe K, Saijo N.
    Jpn J Cancer Res; 1992 Jul 01; 83(7):754-60. PubMed ID: 1325432
    [Abstract] [Full Text] [Related]

  • 15. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
    Basu A, Weixel K, Saijo N.
    Cell Growth Differ; 1996 Nov 01; 7(11):1507-12. PubMed ID: 8930400
    [Abstract] [Full Text] [Related]

  • 16. Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines.
    Hong WS, Saijo N, Sasaki Y, Minato K, Nakano H, Nakagawa K, Fujiwara Y, Nomura K, Twentyman PR.
    Int J Cancer; 1988 Mar 15; 41(3):462-7. PubMed ID: 3346112
    [Abstract] [Full Text] [Related]

  • 17. Chemosensitivity and radiosensitivity of small cell lung cancer cell lines studied by a newly developed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) hybrid assay.
    Hida T, Ueda R, Takahashi T, Watanabe H, Kato T, Suyama M, Sugiura T, Ariyoshi Y, Takahashi T.
    Cancer Res; 1989 Sep 01; 49(17):4785-90. PubMed ID: 2547517
    [Abstract] [Full Text] [Related]

  • 18. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo.
    Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H.
    J Exp Clin Cancer Res; 2010 Jul 01; 29(1):87. PubMed ID: 20594324
    [Abstract] [Full Text] [Related]

  • 19. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
    Sasaki Y, Shinkai T, Eguchi K, Tamura T, Ohe Y, Ohmori T, Saijo N.
    Cancer Chemother Pharmacol; 1991 Jul 01; 27(4):263-70. PubMed ID: 1847845
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
    Kim DK, Kim HT, Cho YB, Tai JH, Ahn JS, Kim TS, Kim KH, Hong WS.
    Cancer Chemother Pharmacol; 1995 Jul 01; 35(5):441-5. PubMed ID: 7850928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.